Literature DB >> 2474012

Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin.

S Miyagawa1, T Okuchi, Y Shiomi, K Sakamoto.   

Abstract

Skin eruptions with features of subacute cutaneous lupus erythematosus occurred in a patient with dermatomyositis who was taking griseofulvin. The patient had antibodies against SSA/Ro and SSB/La antigens. Skin rashes disappeared after discontinuation of griseofulvin and recurred on challenge with the drug. These findings support previous studies that the photoactive drug may be synergistic with anti-SSA/Ro antibody to produce lesions of subacute cutaneous lupus erythematosus.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2474012     DOI： 10.1016/s0190-9622(89)80031-3

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


  5 in total

Review 1.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

Review 2.  Anti-Ro(SSA) and anti-La(SSB) antibodies in autoimmune rheumatic diseases.

Authors:  P Youinou; Y Adler; S Muller; A Lamour; D Baron; R L Humbel
Journal:  Clin Rev Allergy       Date:  1994

3.  [Terbinafine-induced subacute cutaneous lupus erythematosus. Case report and review of the literature].

Authors:  T Matthes; M Hagedorn
Journal:  Hautarzt       Date:  2004-07       Impact factor: 0.751

4.  Nephrotic syndrome related to systemic lupus erythematosus after griseofulvin therapy.

Authors:  M Bonilla-Felix; R Verani; L G Vanasse; A Hebert
Journal:  Pediatr Nephrol       Date:  1995-08       Impact factor: 3.714

5.  Griseofulvin associated with drug reaction with eosinophilia and systemic symptoms (DRESS).

Authors:  Corinne Maiolo; Christopher Ross; Jan Ibbetson; Daniel Kearney
Journal:  JAAD Case Rep       Date:  2016-08-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.